Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...

NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.

There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...

According to a new feature by the Washington Post, approximately 16 million American adults are on GLP-1 drugs such as ...

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

By Dennis Thompson HealthDay ReporterMONDAY, July 14, 2025 (HealthDay News) — Good news for women of a certain age: Hormone ...

Wegovy, a weight loss drug, is gaining popularity for its effectiveness, but experts emphasize that it's most successful when ...

The new arrangement could cut patients' copays to $25 per month, or less, for Wegovy, Zepbound, Ozempic and Rybelsus ...

Research indicates GLP-1 receptor agonists, like Ozempic, may elevate testosterone levels in men while promoting weight loss.

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

Most of the scariest side effects of weight-loss drugs like Ozempic, Wegovy, and Zepbound have been gastrointestinal.